Biomarin Pharmaceutical (BMRN) Tax Rate (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Tax Rate came in at 25.27% in Q1 2026, up 326.0% YoY from 5.93% in Q1 2025, and up 135.33% on a QoQ basis from 71.52% in Q4 2025.
Analysis
Biomarin Pharmaceutical (BMRN) Tax Rate (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Tax Rate data on file, last reported at 25.27% in Q1 2026.
- Quarterly Tax Rate rose 326.0% year-over-year to 25.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30.3% (up 800.0% YoY) and the FY2025 annual result came in at 27.69%, up 648.0% from the prior year.
- Tax Rate rose to 25.27% in Q1 2026, from 71.52% in the prior quarter.
- In the past five years, Tax Rate ranged from a high of 98.58% in Q4 2022 to a low of 249.37% in Q3 2022.
- A 5-year average of 1.81% and a median of 18.89% in 2024 frame the typical range for Tax Rate.
- Annual changes were most pronounced in 2022 — Tax Rate tumbled 27031 bps — and 2023, when it surged 25247 bps.
- Tracing BMRN's Tax Rate over 5 years: stood at 98.58% in 2022, then plunged by 106 bps to 5.42% in 2023, then surged by 586 bps to 26.35% in 2024, then slumped by 371 bps to 71.52% in 2025, then soared by 135 bps to 25.27% in 2026.
- The last three Tax Rate figures came in at 25.27% (Q1 2026), 71.52% (Q4 2025), and 16.79% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.98% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 15.11% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -10.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 24.15% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 7.49% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.71% |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | 27.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.08% |
| Mar 31, 2026 | 25.27% |
| Dec 31, 2025 | -71.52% |
| Sep 30, 2025 | -16.79% |
| Jun 30, 2025 | 19.25% |
| Mar 31, 2025 | 22.01% |
| Dec 31, 2024 | 26.35% |
| Sep 30, 2024 | 21.10% |
| Jun 30, 2024 | 18.89% |
| Mar 31, 2024 | 16.00% |
| Dec 31, 2023 | -5.42% |
| Sep 30, 2023 | 3.10% |
| Jun 30, 2023 | 20.86% |
| Mar 31, 2023 | 10.40% |
| Dec 31, 2022 | 98.58% |
| Sep 30, 2022 | -249.37% |
| Jun 30, 2022 | 20.62% |
| Mar 31, 2022 | 9.98% |
| Dec 31, 2021 | 13.03% |
| Sep 30, 2021 | 20.94% |